Page 20 - Wondergem
P. 20
Chapter 1
Table 1: continued
Therapy
author
TFL patients
RS/P
U/R
Phase
therapy detail
ORR
OS
Chen 2001
35(100)
RS
R
n/a
eto-mel-TBI
100(74/26)
5yr37%
Eide 2010
30(100)
P
R
2
BEAM
83 (60/23)
5yr47%
Foran 1998
27(100)
RS
U+R
n/a
Cy-TBI
100 (31/69)
5yr52%
Le Gouil 2002
5(33)
P
R
2
HDT cy-TBI
100
2yr 80%
Holman 2012
2(13)
P
R
2
various
100
5yr50%
Kasamon 2011
12(15)
P
R
2
bu-cy or cy-TBI purged
ng
4yr58%
Laudi 2004
9(14)
RS
R
n/a
various
ng
4yr 44%
Sablof f 2007
23(17)
RS
R
n/a
BEAM or CBV
ng
5yr56%
Schouten 1989
10(56)
RS
U+R
n/a
various
60 (40/20)
2yr 40%
AlloSCT
Hamadani 2008
Smith 2009 Villa 2013
Williams 2001 Clavert 2010
Hamadani 2008 Mortensen 2012 Ramadan 2008
Ban Hoef f fen 2013
Morley 2008
Reddy 2012 Villa 2013
Link 2013
24(100) RS R n/a
25(45) RS U+R n/a 105(100) RS U+R n/a
50(100) RS U+R n/a 14(73) RS U+R n/a
8(100) RS R n/a 16(40) RS U+R n/a 40(100) RS R n/a
118(100) RS n/a
63(100) RS U+R n/a 24(100)
51(100) RS U+R n/a
172(100) RS U+R n/a 60(100) RS U+R n/a
Bu-Cy/BEAM/CBV
bu-eto-cy
ASCT eto/mel/tbi
ASCT various flu-bu-ATG
various RIST flu-TBI
various myeloablative
R-CHOP-ASCT- alloSCT
CHOP-ASCT-no treatment
CHOP group separate
ASCT/alloSCT RC vs auto vs allo
RC and ASCT
74 (66/8)
ng
48 reaches AuSCT
77 (62/15) 78 (71/7)
88 (88/0) ng
87 (32/57)
all together
RC< 60 n=19
ASCT < 60 n=24
alloSCT < 60 n=18
ng 63%
100(69/31) before?
RC: ASCT alloSCT RC ASCT
5yr52%
4yr 64%
3yr52%
5yr51% 4yr71%
4yr 66%
5yr78% 5yr23%
2yr 68%
2yr59% 2yr74%
2yr65%
med 10 m
med 24 m
5yr62%
5yr61% 5yr65% 5yr46% 5yr66% ng
Doocey 2005
16(36)
RS
R
n/a
cy-TBI-eto
74 (37/37)
5yr31%
Khouri 1998
2(13)
RS
R
n/a
fludarabine based
100 (50/50)
2yr0%
Novitzky 2007
11(28)
RS
U+R
n/a
various + alemtuzumab
ng
5yr68%
Rezvani 2008
16(26)
RS
R
n/a
flu-TBI
ng
3yr18%
Thomson 2008
18(38)
RS
U+R
n/a
flu-mel- alemtuzumab
ng
4yr61%
multiple therapies
18